The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKcs-mediated DNA damage responses

被引：0
|
作者：
Mukherjee, Bipasha [1 ]
Tomimatsu, Nozomi [1 ]
Amancherla, Kaushik [1 ]
Camacho, Cristel [1 ]
Burma, Sandeep [1 ]
机构：
[1] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/1538-7445.AM2012-3745
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3745
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Radiation Sensitization of Head and Neck Tumor Cells using the dual PI3K/mTOR Inhibitor NVP-BEZ235
    Balzer, V.
    Subtil, F.
    Dikomey, E.
    Engenhart-Cabillic, R.
    Schoetz, U.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2021, 197 (SUPPL 1) : S233 - S233
  • [22] Dual PI3K/mTOR inhibitor NVP-BEZ235 in combination with AKT inhibitor MK2206 in esophageal carcinoma cells
    Yu, Hao
    Shi, Ni
    Pan, Zui
    Chen, Tong
    CANCER RESEARCH, 2014, 74 (19)
  • [23] NVP-BEZ235, a dual PI3K/mTOR inhibitor, may be effective for ovarian clear cell carcinoma cells
    Oishi, Tetsuro
    Itamochi, Hiroaki
    Nonaka, Michiko
    Sato, Seiya
    Naniwa, Jun
    Uegaki, Kazunori
    Sato, Shinya
    Shimada, Muneaki
    Terakawa, Naoki
    Kigawa, Junzo
    Harada, Tasuku
    CANCER RESEARCH, 2011, 71
  • [24] The dual PI3K/mTOR inhibitor NVP-BEZ235 inhibits proliferation and induces apoptosis of burkitt lymphoma cells
    Li, Chuntuan
    Xin, Pengliang
    Xiao, Huifang
    Zheng, Yan
    Huang, Yuanling
    Zhu, Xiongpeng
    CANCER CELL INTERNATIONAL, 2015, 15
  • [25] Combination strategy of gemcitabine with the dual PI3K/mTOR inhibitor NVP-BEZ235 in pancreatic cancer cells.
    Hausmann, E.
    Glienke, W.
    Bergmann, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [26] Retinoblastoma cells activate the AKT pathway and are vulnerable to the PI3K/mTOR inhibitor NVP-BEZ235
    Xie, Chencheng
    Freeman, Matthew J.
    Lu, Huarui
    Wang, Xiaohong
    Forster, Colleen L.
    Sarver, Aaron L.
    Hallstrom, Timothy C.
    ONCOTARGET, 2017, 8 (24) : 38084 - 38098
  • [27] The dual PI3K/mTOR inhibitor NVP-BEZ235 inhibits proliferation and induces apoptosis of burkitt lymphoma cells
    Chuntuan Li
    Pengliang Xin
    Huifang Xiao
    Yan Zheng
    Yuanling Huang
    Xiongpeng Zhu
    Cancer Cell International, 15
  • [28] In vivo antitumor activity of NVP-BEZ235, a dual PI3K/mTOR inhibitor, and RAD001 (everolimus), an mTOR inhibitor, in endometrial cancer
    Shoji, Keiko
    Oda, Katsutoshi
    Nakagawa, Shunsuke
    Ikeda, Yuji
    Kashiyama, Tomoko
    Miyamoto, Yuichiro
    Tanikawa, Michihiro
    Kuramoto, Hiroyuki
    Hiraike-Wada, Osamu
    Yano, Tetsu
    Taketani, Yuji
    CANCER RESEARCH, 2011, 71
  • [29] Genotype-Dependent Efficacy of a Dual PI3K/mTOR Inhibitor, NVP-BEZ235, and an mTOR Inhibitor, RAD001, in Endometrial Carcinomas
    Shoji, Keiko
    Oda, Katsutoshi
    Kashiyama, Tomoko
    Ikeda, Yuji
    Nakagawa, Shunsuke
    Sone, Kenbun
    Miyamoto, Yuichiro
    Hiraike, Haruko
    Tanikawa, Michihiro
    Miyasaka, Aki
    Koso, Takahiro
    Matsumoto, Yoko
    Wada-Hiraike, Osamu
    Kawana, Kei
    Kuramoto, Hiroyuki
    McCormick, Frank
    Aburatani, Hiroyuki
    Yano, Tetsu
    Kozuma, Shiro
    Taketani, Yuji
    PLOS ONE, 2012, 7 (05):
  • [30] DUAL PI3K/MTOR INHIBITOR NVP-BEZ235 HAS POTENT ANTICANCER EFFECTS ON NSCLC HARBORING WILD-TYPE EGFR
    Chen, Yuh-Ling
    Chen, Sz-Shiuan
    Hong, Tse-Ming
    ANTICANCER RESEARCH, 2014, 34 (10) : 5863 - 5863
12345